Saudi Arabia Atopic Dermatitis Therapeutics Market Report 2022 to 2030

Saudi Arabia Atopic Dermatitis Therapeutics Market Analysis

$ 3999

The Saudi Arabia Atopic Dermatitis Therapeutics Market was valued at US $209 Mn in 2022, and is predicted to grow at (CAGR) of 10.3% from 2023 to 2030, to US $458 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), innovative drugs in the pipeline and evolving healthcare landscape. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Regeneron, Eli Lilly, and Astellas, among others.

ID: IN10SAPH435 CATEGORY: Pharmaceuticals GEOGRAPHY: Saudi Arabia AUTHOR: Riddhi Solanki

Buy Now

Saudi Arabia Atopic Dermatitis Therapeutics Market Analysis: Executive Summary

The Saudi Arabia Atopic Dermatitis Therapeutics Market is at around US $209 Mn in 2022 and is projected to reach US $458 Mn in 2030, exhibiting a CAGR of 10.3% during the forecast period.

Atopic dermatitis (AD), commonly known as eczema, is a persistent inflammatory skin condition characterized by redness, itching, and inflammation. It often manifests in localized patches on various body areas and can be exacerbated by factors such as dry skin, stress, and exposure to specific irritants or allergens. Prominent symptoms include intense itching, redness, dryness, and the appearance of small, fluid-filled blisters that may discharge fluid and form crusts. Treatment typically involves a comprehensive approach, incorporating the use of emollients for skin moisturization, topical corticosteroids to reduce inflammation, and, in severe cases, systemic immunosuppressants. Various pharmaceutical companies manufacture medications for atopic dermatitis, with notable examples including Regeneron Pharmaceuticals and Sanofi's Dupixent (Dupilumab), Pfizer's Eucrisa (Crisaborole), and Novartis's Elidel (Pimecrolimus).

It is estimated that the prevalence of AD in Saudi Arabia is approximately 20% in children and 2-10% in adults. The market is being driven by significant factors such as the rising prevalence of AD, steadily growing economy, and supportive government initiatives for the therapeutics industry. However, conditions such as limited affordability, a lack of human resources, and market saturation can restrict the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Rising prevalence of AD: It is estimated that the prevalence of AD in Saudi Arabia ranges from 15-20% in children to about 2-10% of adults. It is most prevalent among children as compared to adults. The surge is driven by factors such as urbanization, lifestyle changes, and genetic predisposition, which propel the market forward in demand for new therapeutics.

Rising economic growth: The economic expansion in Saudi Arabia results in increased disposable income, empowering patients to afford pricier and more advanced treatments, such as biologics. Patients are becoming more knowledgeable and proactive in pursuing advanced treatment alternatives.

Supportive government initiatives: The Saudi government's commitment to enhancing healthcare infrastructure and facilitating access to specialized care positively impacts the atopic dermatitis market. Initiatives such as Vision 2030 highlight a focus on chronic disease management and personalized medicine, fostering a conducive environment for advanced therapeutics.

Market Restraints

Limited affordability: The cost of modern biological therapies is high, posing a financial obstacle for individuals with low incomes and potentially putting a burden on the healthcare system. Certain insurance plans may not include coverage for newer or specialized treatments, placing significant out-of-pocket costs on patients.

Lack of human resource: The uneven distribution of healthcare professionals and facilities throughout the country can present difficulties for certain populations in accessing specialized dermatological care.

Market saturation and competition: A plethora of low-cost generic topical steroids and emollients saturates the market, posing a challenge for newer, pricier therapies to gain traction. Effectively reaching patients in remote areas and creating awareness about advanced treatments necessitate strong marketing and distribution networks, which may be deficient in certain regions.

Healthcare Policies and Regulatory Landscape

Vision 2030 is spearheading a significant overhaul in Saudi Arabia's healthcare sector. Major entities such as the Ministry of Health, the Council of Cooperative Health Insurance, and the SACB play active roles in shaping this landscape, already effecting notable changes, such as the introduction of mandatory health insurance for expatriates. These transformations open up extensive opportunities for pharmaceutical firms. Anticipated changes encompass heightened healthcare spending, enhancements in infrastructure, and potential privatization, all poised to further redefine the regulatory framework.

Securing licenses, particularly in pharmacies, now involves more stringent procedures in accordance with guidelines from the Saudi Food and Drug Authority (SFDA). Staying abreast of evolving regulations becomes essential for pharmaceutical businesses to capitalize on the escalating momentum in Saudi healthcare.

Competitive Landscape

Key Players

Sanofi
Pfizer
AbbVie
Leo Pharma
Novartis
Galderma
AstraZeneca
Almirall
Bayer
Julphar

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Saudi Arabia Atopic Dermatitis Therapeutics Market Segmentation

By Drug Class

Corticosteroids
Calcineurin Inhibitors
Immunosuppressants
Biologic Therapy
PDE-4 Inhibitor
Antibiotics
Antihistamines
Emollients

By Route of Administration

Topic
Oral
Injectable

By Severity type

Mild
Moderate
Severe

By Age Group

18 years and below
19 years and above

By Distribution channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Dermatology Clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.